Payment overview · 2025
General Payments
$236.82
13 reported records · 8 companies
Healthcare provider profile · identity verified
Dean Halbert, M. D.
Allopathic & Osteopathic Physicians|Family Medicine · BEAUMONT, TX · NPI 1497758767
Verified facts
What the public records show
CMS Open Payments records show Dean Halbert, M. D. received $236.82 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.84 | 38.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.75 | 13.8% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$27.82 | 11.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.99 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.86 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.27 | 7.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.19 | 6.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.10 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.82 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 742 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 183 |
| Omeprazole | Omeprazole | 437 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 429 | 134 |
| Gabapentin | Gabapentin | 424 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 129 |
| Lisinopril | Lisinopril | 381 | 113 |
| Metformin Hcl | Metformin Hcl | 376 | 118 |
| Simvastatin | Simvastatin | 371 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 100 |
| Zolpidem Tartrate | Zolpidem Tartrate | 309 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 97 |
| Losartan Potassium | Losartan Potassium | 300 | 90 |
| Trazodone Hcl | Trazodone Hcl | 300 | 108 |
| Allopurinol | Allopurinol | 277 | 77 |
| Tramadol Hcl | Tramadol Hcl | 273 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 81 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 94 |
| Azithromycin | Azithromycin | 258 | 199 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 247 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 81 |
| Furosemide | Furosemide | 182 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 177 | 52 |
| Meloxicam | Meloxicam | 169 | 69 |
| Montelukast Sodium | Montelukast Sodium | 169 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 50 |
| Sertraline Hcl | Sertraline Hcl | 162 | 51 |
| Alendronate Sodium | Alendronate Sodium | 147 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 50 |
| Alprazolam | Alprazolam | 134 | 21 |
| Potassium Chloride | Potassium Chloride | 133 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 38 |
| Carvedilol | Carvedilol | 131 | 39 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 128 | 43 |
| Glipizide | Glipizide | 116 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 110 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 28 |
| Ezetimibe | Ezetimibe | 98 | 28 |
| Glipizide Er | Glipizide | 95 | 34 |
| Finasteride | Finasteride | 92 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 90 | 27 |
| Temazepam | Temazepam | 90 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 89 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 21 |
| Buspirone Hcl | Buspirone Hcl | 77 | 22 |
| Lorazepam | Lorazepam | 77 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 26 |
| Celecoxib | Celecoxib | 75 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 20 |
| Synthroid | Levothyroxine Sodium | 74 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 55 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 21 |
| Famotidine | Famotidine | 71 | 25 |
| Metformin Hcl Er | Metformin Hcl | 69 | 25 |
| Ozempic | Semaglutide | 68 | 22 |
| Nifedipine Er | Nifedipine | 67 | 11 |
| Eliquis | Apixaban | 64 | 17 |
| Atenolol | Atenolol | 58 | 15 |
| Benazepril Hcl | Benazepril Hcl | 58 | 15 |
| Lovastatin | Lovastatin | 58 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 26 |
| Cefdinir | Cefdinir | 56 | 44 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 20 |
| Methylprednisolone | Methylprednisolone | 51 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 19 |
| Fenofibrate | Fenofibrate | 48 | 16 |
| Spironolactone | Spironolactone | 48 | 14 |
| Nateglinide | Nateglinide | 46 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Valsartan | Valsartan | 44 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Estradiol | Estradiol | 41 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 39 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 12 |
| Prednisone | Prednisone | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | 11 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 11 |
| Nystatin | Nystatin | 29 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 15 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 12 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Zonisamide | Zonisamide | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 16 |
| Topiramate | Topiramate | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.82 · 13 records | Novo Nordisk Inc | AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VALTOCO, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error